US Bone Grafts Market to Reach US$2.3 Billion by 2017, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive report on the US Bone Grafts market. The US market for Bone Grafts is projected to reach US$2.3 billion by the year 2017. The need for bone reconstruction in the form of bone grafts cannot be undermined since a weak or complete absence of bone’s structural support results in undue compression on nerves, muscles, and vital organs inducing chronic pain and development of secondary complications. The market for bone grafts is projected to record steady growth driven by an aging population, rising incidences of degenerative intervertebral disc diseases, rise in the number of revision orthopaedic surgeries, rise in spinal fusions in private healthcare and an increasing number of seniors seeking an active lifestyle.

Bone Grafts: A US Market Report

Follow us on LinkedIn – Bone Grafts, in the field of orthopedics, refer to natural or synthetic bones transplanted into the diseased or damaged site to help promote re-generation of new bone. Market for bone grafts is and will continue to be driven by the risks associated with the use of autograft bone, the need to achieve superior and optimum bone fusion, speedy patient recovery, need to eliminate multiple surgeries, rising number of spinal fusion procedures, and growing use of tissue-engineered bone in joint replacements. The market is also expected to gain from commercialization of new, next generation bone growth factors, and launch of innovative new bone products. Bone and joint disorders account for almost half of debilitating conditions in individuals over 50 years of age. With this cohort of the population expected to double by the year 2020, demographics alone will represent a key growth driver in the global orthopedic market. Globally, approximately one million bone-grafting procedures are performed every year on the pelvis, spine, and other body extremities in attempts to repair or reconstruct the bone. Surgeons frequently employ bone grafts or substitute materials to promote bone growth and achieve fusion. Bone grafts are utilized for a variety of orthopedic applications, such as spinal applications, trauma, joint revision, bone void filling, and iliac crest (hip) backfill as well as oral and periodontal repair.

With the focus in the orthopedic industry shifting from the mechanics to the biology of bone healing, orthobiologics is bound to gain traction in the bone grafts market. Orthobiologics, a branch of medical science that utilizes biomaterials, and other biological products with regenerative capabilities to fuse, join, and stimulate bone growth, is one of the rapidly growing segments within the global orthopedic market. In recent years, there has been a tremendous rise in the number of bone substitute products innovated and commercialized. These new generation products are being developed to help improve patient’s quality of life, expand treatment options, while simultaneously lowering healthcare costs. An ideal bone substitute should be cost-effective, structurally similar to natural bone, bio-resorbable, biocompatible, osteoinductive, osteoconductive, and easy to administer and use. However, no currently marketed bone substitute meets all these requirements.

Bone Morphogenetic Protein (BMP) represents the largest product segment in the bone grafts market. BMP stimulates formation of new bone by causing differentiation of stem cells into osteoblasts. Although bone graft substitutes have shown tremendous potential for growth, limited product indications, higher costs of certain substitutes, poor-to-moderate mechanical properties of synthetic substitutes, and factor & cell-based products are some of factors that may constrain growth. Demineralized Bone Matrix (DBM) represents the fastest growing product segment. Demineralized bone matrix (DBM) products continue to remain the preferred grafting material over traditional allografts. DBM exhibits both osteoinductive and osteoconductive properties, with clinical evidence as a viable bone graft extender. With a number of new bone grafts, and bone graft substitute products being approved and launched into the market, patient safety is gradually emerging into the top of the medical community’s priority list. In addition to the ever-present risk of disease transmission, proper utilization of the product as approved by the regulatory authority is also gaining importance.

Major players in the marketplace include AlloSource, Biomet Inc, BioMimetic Therapeutics Inc, DePuy Spine Inc, Exactech Inc., Integra LifeSciences Holdings Corporation, LifeLink Tissue Bank, LifeNet Health, Medtronic Inc, Musculoskeletal Transplant Foundation, NovaBone Products, LLC, NuVasive, Inc., Orthovita Inc, Osiris Therapeutics Inc, Osteotech Inc, RTI Biologics, Inc., Smith & Nephew Plc, Stryker Corporation, Synthes Inc, Wright Medical Technology and Zimmer Holdings, Inc.

The research report titled "Bone Grafts: A US Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, issues, strategic industry activities, and profiles of major companies worldwide. The report provides market estimates and projections (US$ Million) for product segments Standard Allografts, Machined Bone Allografts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Protein (BMP), Platelet Concentrators and Synthetic Bone Grafts.

For more details about this comprehensive market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website